EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes

Tim Heise iD, J Hans DeVries iD, Shweta Urva iD, Jing Li, Edward J Pratt iD, Melissa K Thomas iD, Kieren J Mather, Chrisanthi A Karanikas, Julia Dunn iD, Axel Haupt iD, Zvonko Milicevic iD, Tamer Coskun iD

Diabetes Care · 01.05.2023 · 46 (5) · 998-1004

DOI: 10.2337/dc22-1710 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, online erschienen am 01.03.2023. Verfasst von Tim Heise und 11 weiteren Autor:innen. Beteiligte Einrichtung: 1Profil, Neuss, Germany. Hauptthemen laut MEDLINE: Appetite, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 199-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To evaluate the effects of tirzepatide on body composition, appetite, and energy intake to address the potential mechanisms involved in body weight loss with tirzepatide. RESEARCH DESIGN AND METHODS In a secondary analysis of a randomized, double-blind, parallel-arm study, the effects of tirzepatide 15 mg (N = 45), semaglutide 1 mg (N = 44), and placebo (N = 28) on body weight and composition, appetite, and energy intake were assessed at baseline and week 28. RESULTS Tirzepatide treatment demonstrated significant reductions in body weight compared with placebo and semaglutide, resulting in greater fat mass reduction. Tirzepatide and semaglutide significantly reduced appetite versus placebo. Appetite scores and energy intake reductions did not differ between tirzepatide and semaglutide. CONCLUSIONS Differences in energy intake during ad libitum lunch were not sufficient to explain the different weight outcomes. Further evaluation is needed to assess mechanistic differences related to tirzepatide actions on 24-h energy intake, substrate utilization, and energy expenditure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AppetiteDiabetes Mellitus, Type 2HumansObesityBody WeightEnergy IntakeDouble-Blind MethodTirzepatide

Substanzen

Tirzepatide

Autor:innen und Institutionen

  • 1Profil, Neuss, Germany.
  • 2Eli Lilly and Company, Indianapolis, IN.

ORCID-Profile: Tim Heise, J Hans DeVries, Shweta Urva, Edward J Pratt, Melissa K Thomas, Julia Dunn, Axel Haupt, Zvonko Milicevic, Tamer Coskun

Förderung

  • Eli Lilly and Company

Zitieren

APA

Heise, T., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Thomas, M. K., Mather, K. J., Karanikas, C. A., Dunn, J., Haupt, A., Milicevic, Z., & Coskun, T. (2023). Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care, 46(5), 998-1004. https://doi.org/10.2337/dc22-1710

Vancouver

Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, et al. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care. 2023;46(5):998-1004. doi:10.2337/dc22-1710

BibTeX
@article{Heise2023,
  author = {Heise, Tim and DeVries, J Hans and Urva, Shweta and Li, Jing and Pratt, Edward J and Thomas, Melissa K and Mather, Kieren J and Karanikas, Chrisanthi A and Dunn, Julia and Haupt, Axel and Milicevic, Zvonko and Coskun, Tamer},
  title = {Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes},
  journal = {Diabetes Care},
  year = {2023},
  volume = {46},
  number = {5},
  pages = {998--1004},
  doi = {10.2337/dc22-1710}
}
Kostenlos starten →